8-K: Align Technology Reports Q1 2026 Results, Stock Repurchase Plan

Align Technology announced its first quarter 2026 financial results, reporting $1,040.1 million in total revenues, a 6.2% increase year-over-year, and reaffirming its fiscal 2026 guidance.

Summary

• Align Technology reported Q1 2026 total revenues of $1,040.1 million, a 6.2% increase year-over-year, driven by a 6.7% increase in Invisalign Clear Aligner shipments to 685.7 thousand cases.
• Clear Aligner revenues were $856.0 million, up 7.4% year-over-year, while Imaging Systems and CAD/CAM Services revenues were $184.1 million, up 0.9% year-over-year.
• GAAP diluted net income per share was $1.57, and non-GAAP diluted net income per share was $2.58.
• The company announced a $200 million stock repurchase plan, with $800 million remaining under its existing program.
• Align reaffirmed its full-year fiscal 2026 guidance, expecting worldwide revenue growth of 3% to 4% year-over-year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with better-than-expected results and a reaffirmed strong outlook, despite some currency headwinds and geopolitical concerns.

Positives

• Record Q126 Invisalign Clear Aligner shipments of 685.7 thousand, a 6.7% increase year-over-year.
• Total revenues increased 6.2% year-over-year to $1,040.1 million.
• Clear Aligner revenues increased 7.4% year-over-year to $856.0 million.
• Imaging Systems and CAD/CAM Services revenues increased 0.9% year-over-year to $184.1 million.
• Non-GAAP diluted net income per share of $2.58 exceeded expectations.
• Double-digit growth in EMEA, APAC, and LATAM regions for Clear Aligners.
• Continued stability in North America for Clear Aligners.
• Reaffirmed full-year fiscal 2026 guidance for revenue growth (3-4%) and operating margin improvements.

Negatives

• Total revenues were down 0.7% sequentially.
• Q1'26 gross margin of 70.8% was unfavorably impacted by foreign exchange.
• Q1'26 operating margin of 13.6% was unfavorably impacted by foreign exchange.
• GAAP net income decreased 16.9% sequentially.
• Non-GAAP net income decreased 21.8% sequentially.

Risks

• Uncertainty and potential adverse impacts on patient traffic, consumer demand, and shipping/freight due to ongoing military action in the Middle East.
• Potential for further escalation of the conflict in the Middle East, sustained constraints on oil and gas supplies, or broader softening in consumer and patient sentiment.
• Adverse foreign exchange fluctuations.
• Changes to currently applicable duties, tariffs, or other fees that could impact the business.
• Macroeconomic conditions, including fluctuations in foreign currency exchange rates, higher interest rates, market volatility, inflation, and general economic weakness.
• Geopolitical events, such as wars and military conflicts, which could result in disruptions to the supply chain and global economy.
• Trade policies, tariffs, customs duties and fees, and retaliatory actions.

Future Outlook

Align Technology reaffirms its full-year fiscal 2026 guidance, expecting worldwide revenue growth of 3% to 4% year-over-year, with Clear Aligner volume growth in the mid-single digits. The company anticipates GAAP operating margin to be slightly below 18.0% and non-GAAP operating margin to be approximately 23.7%. For Q2 2026, revenues are projected to be between $1,040 million and $1,060 million, representing 3% to 5% year-over-year growth. The company expects some impact on demand from the Middle East conflict in Q2.

Management Comments

• "Were pleased to report another better-than-expected quarter, with Q126 revenues, Clear Aligner volumes, and both GAAP and nonGAAP operating margins exceeding our outlook, reflecting continued execution against our strategic priorities and resilience across our global business."
• "First quarter revenues of $1.04 billion increased 6.2% year-over-year, driven primarily by higher Clear Aligner volumes and increased ASPs."
• "As we move forward in 2026, our focus is on maintaining discipline as we strategically invest in innovation and growth opportunities, including advancing digital dentistry through the Align Digital Platform, scaling our iTero Lumina ecosystem, expanding internationally with localized strategies, and continuing to build a differentiated portfolio for teens and growing patients."

Industry Context

StockSavvy.ai notes that Align Technology's Q1 2026 results demonstrate continued strength in the clear aligner market, with international growth outpacing North America. The company's focus on digital dentistry and its integrated platform positions it well within the evolving orthodontic and restorative dentistry landscape, despite macroeconomic headwinds and geopolitical uncertainties.

Comparison to Industry Standards

• The year-over-year revenue growth of 6.2% for Align Technology in Q1 2026 is a solid performance in the medical device sector, particularly for a company in a specialized segment like clear aligners. This growth rate generally exceeds the average growth seen in broader medical device markets, which can fluctuate significantly based on product cycles and market penetration.
• The gross margin of 70.8% (GAAP) is exceptionally high, indicating strong pricing power and efficient manufacturing processes, which is a benchmark for high-value medical technology companies. Competitors in adjacent fields like dental implants or general dental equipment often report lower gross margins.
• The company's investment in innovation, as highlighted by its focus on the Align Digital Platform and iTero Lumina ecosystem, aligns with industry trends towards digitalization and integrated solutions. Companies like Dentsply Sirona and Envista Holdings are also investing heavily in digital solutions, but Align's established clear aligner base provides a unique ecosystem advantage.

Legal Proceedings

• The company is no longer subject to certain tariffs imposed under the International Emergency Economic Powers Act (IEEPA) following a Supreme Court ruling on February 20, 2026, but is now subject to new, temporary tariffs under Section 122 of the Trade Act of 1974, effective February 24, 2026. This change is not expected to have a material impact.

Stakeholder Impact

• Shareholders: Benefit from the announced $200 million stock repurchase program, which can increase shareholder value through reduced share count and potential EPS accretion. The reaffirmed guidance also provides a positive outlook.
• Employees: Continued investment in innovation and growth may lead to job creation and development opportunities. However, the company has also undertaken restructuring plans in previous quarters to reduce headcount and increase efficiency.
• Customers (Doctors/Dentists): Continued focus on product innovation (e.g., iTero Lumina) and digital platform integration aims to improve practice efficiency and patient outcomes.
• Suppliers: Potential for increased demand due to revenue growth, but also subject to global supply chain risks mentioned in the filing.

Next Steps

• Continue strategic investment in innovation and growth opportunities, including the Align Digital Platform and iTero Lumina ecosystem.
• Expand internationally with localized strategies.
• Build a differentiated portfolio for teens and growing patients.
• Repurchase an additional $200.0 million of common stock over a six-month period beginning on or about May 1, 2026.

Key Dates

Recommendation

The company delivered better-than-expected results and reaffirmed its guidance, indicating operational strength. However, the ongoing geopolitical risks in the Middle East and potential macroeconomic headwinds introduce significant uncertainty that warrants a cautious approach. While the stock repurchase program is positive, the current environment suggests holding the stock to assess the impact of these external factors before considering a stronger recommendation.

Keywords

Align Technology, Invisalign, Clear Aligners, Q1 2026 Earnings, Financial Results, iTero Scanners, Stock Repurchase, Digital Dentistry